Inactivating mutations in the MLH1 gene cause the cancer predisposition Lynch syndrome, but for small coding genetic variants it is mostly unclear if they are inactivating or not. Nine such MLH1 variants have been identified in South American colorectal cancer (CRC) patients (p. Tyr97Asp, p.His112Gln, p.Pro141Ala, p.Arg265Pro, p.Asn338Ser, p.Ile501del, p.Arg575Lys, p.Lys618del, p.Leu676Pro), and evidence of pathogenicity or neutrality was not available for the majority of these variants. We therefore performed biochemical laboratory testing of the variant proteins and compared the results to protein in silico predictions on structure and conservation. Additionally, we collected all available clinical information of the families to come to a conclusion concerning their pathogenic potential and facilitate clinical diagnosis in the affected families. We provide evidence that four of the alterations are causative for Lynch syndrome, four are likely neutral and one shows compromised activity which can currently not be classified with respect to its pathogenic potential.
| I N TR ODU C TI ON
Lynch syndrome (MIM #120435) is a heritable condition associated with a greatly increased lifetime risk of colorectal cancer (CRC) (70-80%), endometrial cancer (50-60%), stomach cancer (13-19%) , ovarian cancer (9-14%), cancer of the small intestine, the biliary tract, brain as well as carcinoma of the ureters and renal pelvis. 1 It is caused by an inactivating mutation of a DNA mismatch repair (MMR) gene: MLH1
(MIM# 120436), MSH2 (MIM #609309), MSH6 (MIM #600678), and PMS2 (MIM #600259) or to deletions of the 3 0 portion of the EPCAM gene. 2, 3 Since Lynch syndrome does not provide a characteristic phenotype enabling clinical diagnosis, diagnosis requires identification of a causative (inactivating) mutation in a MMR gene. Besides establishing the diagnosis for the affected patient, this subsequently enables predictive testing of family members, and therefore early surveillance and cancer prevention methods provide significant benefit for affected individuals.
While the relevant genes are known and tools for detecting genetic alterations are readily available, a significant proportion of alterations identified in patients cannot straightforwardly be classified as inactivating and therefore pathogenic. 3, 4 This exemplarily accounts for many small coding variants like missense alterations and small insertions or deletions, as well as for noncoding variants outside the highly conserved splicing motifs which may affect splicing in an unpredictable fashion. For these variants, pathogenicity clarification must be performed. Different lines of evidence, either directly from clinical patient or family data, or indirect, from laboratory or in silico predictions, may be used. Different approaches have been suggested to solve this problem, 5 and for some lines of evidence, likelihood ratios (LRs) have been determined to integrate evidence into a probability score 6 of pathogenicity which allows classification in a 5-tiered system, 4 ideally yielding a clear classification of a variant.
However, for other types of small coding variants, as well as for so-called private variants for which sufficient appropriate information is usually lacking, pathogenicity classification requires alternative procedures. In these cases, it is possible to perform functional testing to assess the impact of a variant, which has frequently served to approach a classification for such variants. 5, [7] [8] [9] [10] We have previously shown that small, coding variants most frequently cause destabilization and/or inactivation of the resulting MLH1
protein, and provided reference variants that facilitate translation of biochemical test results in pathogenicity information. 11 Genetic counselling and testing has recently been introduced in Latin America and has led to the identification of several yet uncharacterized genetic variants in MLH1. 12 In this work, we have tested nine small coding variants identified in 9 South American individuals. We describe the experimental evaluation of their effects at protein level.
We further discuss the results in context with all the available clinical information that has been gathered from the affected patients and their families, and also assess the structural role of the altered residues and their conservation in evolution. Patients were informed about their inclusion into the registries and written informed consent was obtained from all participants during genetic counseling sessions.
| Nomenclature and classification of genetic variants
The nomenclature guidelines of the Human Genome Variation Society (HGVS) were used to describe the detected genetic variants. 19 The (likely pathogenic), class 3 (uncertain variants or variants of unknown significance, VUS), class 2 (likely not pathogenic) and class 1 (not pathogenic). 4 Syntax of all variants was verified using Mutalyzer 20 using the current MLH1 reference sequence (NM_000249.3).
| Cell lines
HEK293T cells were used for this work and were kindly provided by 
| Protein expression and quantification
pcDNA3-MLH1, pSG5-PMS2, and the HEK293T cell line have been described previously. 21, 22 Missense variants were generated by site- 
| MMR activity
The MMR activity of MLH1 variants was scored in vitro as described previously. 11, 23 Briefly, protein extracts were mixed with 35 ng of DNA substrate containing a G-T mismatch and a 3 0 single-strand nick at a distance of 83 bp. After incubation at 378C, the DNA substrate was purified and digested with EcoRV and AseI. The restriction fragments were separated in agarose gels and analyzed using GelDoc XR plus detection and QuantityOne software (Bio-Rad). The repair efficiency (e) was calculated as: e 5 (intensity of bands of repaired substrate)/(intensity of all bands of substrate). This result is independent of the amount of DNA recovered through plasmid purification. The typical total repair efficiencies ranged from 50 to 90%. The repair efficiency of MLH1 variants was analyzed in direct comparison to a wild-type protein that had been produced in parallel, and calculated as e(relative) 5 e(variant)/e (wild type) 3 100.
| Structural analyses
Function-structure evaluations were performed with an updated model of human MutLa (MLH1-PMS2) 9 based on the N-terminal domains of human PMS2 NTD 24 and an homology model of MLH1-NTD. 23 The Cterminal domains (CTD) were built by homology modeling using yeast MutLa (PDB codes: 4E4W and 4FMN) and human MLH1 (PDB code: 3RBN) structures as templates. 4E4W, the highest resolution yeast MutLa structure, was used for modeling the conformation of the dimeric interface and as a template for modeling missing regions of MLH1 and the whole PMS2 subunit. 4FMN was used to model one loop missing from 4E4W structure. The MIP-box peptide (a fragment of NTG2) was taken from 4FMN structure and the zinc ions from 4E4W. The modeling templates were identified and selected using
MODexplorer. 25 The target-template alignment used for modeling PMS2 was evaluated and refined using MODalign. 26 The final model was constructed after exporting the alignments from MODexplorer Although family cancer disease information was available for six variant carriers (Supporting Information Figure S1 ), it was not possible to perform additional genetic analyses in their relatives to assess cosegregation, which is a highly reliable method for the assessment of pathogenicity. Moreover, no sufficient information on molecular tumor traits (microsatellite instability and BRAF status) could be used for pathogenicity classification by Bayesian integrative multifactorial analysis 6 (Table 1) . For assessing pathogenicity, we therefore had to rely on alternative ways, primarily functional testing of the genetic variants in vitro.
| Functional analysis of the MLH1 variants
Loss of protein stability (resulting in absence of protein) and loss of repair activity are both directly associated with disease. Therefore, testing these parameters provides significant information for pathogenicity assessment.
The most frequent consequence of small coding alterations in MLH1 has been shown to be a decrease of the protein stability, which can be determined by expression of the variant cDNA. 11 Decreases in protein stability entail lower protein levels, which, even if the protein is functional, causes loss of repair activity below a certain threshold. 11, 33 In order to translate expression defects into pathogenicity statements, we used previously established reference variants. 11 We applied reference variant MLH1 p.Ala681Thr, which allows to identify variants whose destabilization is severe enough to confer a pathogenic effect in humans due to the low cellular protein levels. Additionally, the neutral polymorphism MLH1 p.Val716Met was used as a reference for clinically neutral defects of stability. 11 We thoroughly assessed the expression levels of all variants in direct comparison to wildtype MLH1 protein and the two reference variants ( Figure 1A) . Results of several independent experiments were analyzed ( Figure 1B) . Six of the variants were at least as strongly expressed as the wildtype protein and therefore do not display stability problems. In contrast, three variants displayed stability decreases similar or stronger than the reference variant: p.Arg265Pro, p.Lys618del and p.Leu676Pro. In two of these cases, expression was significantly below the reference variant for pathological expression defects (P < .05). For these strongly destabilized variants, a pathogenic defect can be concluded since insufficient MLH1 protein is available in the cell.
11
Another major reason for pathogenicity of small coding MLH1 variants is when these confer catalytic inactivity of the variant MLH1 protein. Since the major task of MLH1 protein is supporting DNA mismatch repair, we assessed the ability of the variants to perform the repair reaction in vitro (Figure 2A ). Several independent experiments were performed to validate the results ( Figure 2B ). 
| Conservation and structural roles of the affected residues
Analysis of the structural positions and conservation of variant residues can explain and thereby confirm the functional results of mutational studies. We therefore analyzed the conservation and considered the positions of the affected residues in a structural model of the MutLa heterodimer ( Figure 3 ).
Tyr97 is located in the "ATP lid", a highly conserved structure vital for functionality of the ATPase. [34] [35] [36] The nonconservative substitution of tyrosine to aspartate is expected to disturb the ATPase, explaining the observed loss of catalytic function and corroborating a pathogenic effect.
His112 is located in an extensive b-sheet that forms the back of the ATPase pocket. This residue is involved in interaction of MLH1 with the MutSa. 23 While inversion of the side-chain charge abolished interaction and rendered MLH1 DNA repair deficient, 23 the less drastic substitution to glutamine described here had a milder effect on DNA repair.
Pro141 is in a similar position, albeit on the other side of the b-sheet.
A specific role in protein structure or function is not obvious. Moreover, Rossi et al. 30 Tournier et al. 31 Hardt et al. Rossi et al. 30 Rossi et al. 12 Valentin et al. Abbreviations: ACI/ACII, family meets Amsterdam criteria I or II; BC, breast cancer; CRC, colorectal carcinoma; GC, gastric cancer; IHC, immunohistochemistry results; MSI-H, microsatellite instability-high in tumor (when 2 markers where unstable. MSI-L, microsatellite instability low (when one of the markers was unstable); MSS, microsatellite stable (when none of the markers were unstable); n.a., not applicable; n.d., no data; n.r., not reported.
alanine is frequently present in this position in other organisms (Table 2 and Supporting Information Figure S1 ), strongly suggesting that it is a neutral substitution, which is confirmed by the biochemical results.
Arg265 is located in a highly conserved loop. It establishes a sidechain hydrogen bond to the ATPase pocket. Therefore, it has been suggested to be a detector switch that transmits ATPase signals to conformational changes. 35 A substitution of this highly relevant residue to serine has been described before and was also found to abolish repair activity. 37 Since the residue exerts its biochemical effects through its side chain, the mutation to proline can be expected to display an even more damaging defect, explaining the biochemical loss of function of the variant and corroborating a pathogenic effect.
Asn338 is located in the unstructured linker connecting the N-and Cterminal domains. This linker is not conserved nor crystallized and therefore not present in the structural model. This alone argues against a relevant role of Asn338 in MLH1. Moreover, substitutions for serine in this position are present in many organisms (Table 2 and Supporting Information Figure S2 ), corroborating the functional finding that the substitution is neutral.
Ile501 also belongs to this linker region, but it is present in the structure of the C-terminal domains. It is located in a loop, therefore its deletion does not affect secondary structure. Since the linker region is highly variable not only in sequence but also in length, deletions or insertions seem to be largely acceptable without loss of function. These considerations are in good agreement with the experimental finding that it did not affect biochemical functionality of MLH1.
Arg575 is located in the conserved C-terminal domain. It connects a b-sheet secondary structure with a loop. It is located on the protein surface, and far from functional core regions of the CTD like the zinc binding, 38 dimerization, 39, 40 and endonuclease 38, 41 domains, and it is poorly conserved. Moreover, this conservative substitution is also frequently present in MLH1 proteins from other organisms ( Table 2 and Supporting Information Figure S3 ), corroborating that it is a neutral exchange, which is consistent with the biochemical findings.
Deletion of lysine 618 affects the center of an a-helix. Consequently, the deletion causes a rotation of the C-terminal residues around the helix axis and distort the orientation of internal (hydrophobic) and external (hydrophilic) residues. Therefore, it can be expected to severely affect protein structure (and function), which is reflected by the low stability of the mutant protein.
Leu676 is located in the middle of another a-helix, within a conserved structural three-helix motif that we have shown before to be very sensitive to substitutions which regularly cause severe protein destabilization. 11 Therefore, the functional finding of severe instability is fully consistent with this substitution to the structure breaker amino acid proline.
A different substitution of this position (Leu676Arg) has been found to have the same defect before and was therefore considered pathogenic. however, rather suggests a moderate, if any, pathogenic effect. Another observation that supports neutrality of this variant is its frequency in some control populations, which approximates the general incidence of Lynch syndrome (Table 1) : it is present at a rate of 1:8650 in East Asia, while the general incidence of Lynch syndrome, that is, all pathogenic mutations in all relevant genes, has been estimated to 1:660-1:2200. 42 One individual from Colombia carried the MLH1 p.Pro141Ala, for which we did not find biochemical evidence for conferring a loss of function. Moreover, alanine in this position seems evolutionary acceptable because it occurs naturally in MLH1 proteins of 8% of all analyzed organisms (Table 2) , strongly suggesting neutrality of this substitution. Additionally, the variant showed co-occurrence in the carrier with a pathogenic mutation in MSH2. While this invalidates use of the medical data for interpretation of the specific effect of Pro141Ala, cooccurrence of a pathogenic variant with an unclear variant is generally considered to make pathogenicity less likely for the unclear variant. in general, expected to be worse and harder to predict than substitutions.
However, this deletion had no impact on biochemical performance of MLH1, and this was in good agreement with the low conservation and structural position of the deleted residue at the end of the highly variant linker region of MLH1. We therefore consider it to be likely neutral.
In contrast, the other one-residue deletion in this study (Table 1) , but the variant has not been found in 280 healthy controls. 15 In our analysis, this alteration abrogated stability and repair activity of MLH1, strongly suggesting causality for the cancer predisposition in these two families. 10 this was not possible in these cases.
| D I SCUSSION
We therefore had to rely on functional analysis in combination with other lines of evidence to approach a classification for these variants and facilitate diagnosis for the affected families.
We used a previously established robust method that allows to deduce pathogenicity information from functional evidence, and also used other lines of evidence (from evolutionary information, protein structure and family clinical data). Comprehensive analysis showed that evidence for pathogenicity or neutrality was consistent: it coherently supported that two alterations confer a pathogenic effect by catalytic inactivation (the two ATPase mutations, p.Tyr97Asp and p.Arg265Pro).
For two further alterations, consistent evidence suggested a pathogenic effect by destruction of protein integrity (p.Lys618del and p.Leu676Pro).
Conversely, findings for another four variants coherently supported neutrality: they showed no detectable defects in functionality. While this finding is usually hampered by the caveat that the applied biochemical assay system may not reflect all aspects of biological function, in these cases we also found that the investigated patient substitutions occur quite frequently in evolution. This observation strongly supports neutrality similarly to finding a significant frequency of a given variant in unaffected control populations. Moreover, one variant (Pro141Ala) cooccurred with a clearly pathogenic variant in its carrier (Table 1) , which is also considered a strong indicator of neutrality. 
